Semaglutide for metabolic dysfunction associated steatotic liver disease (MASH).
May 02, 2025•22 min•Ep. 117
Listen to this episode in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episode description
Takeaways
- MASH is a significant obesity-related complication.
- Semaglutide shows promise in treating MASH.
- Weight loss is crucial for improving liver health.
- Bariatric surgery remains the most effective treatment.
- The Essence trial indicates a 63% resolution of NASH.
- New medications are being developed for obesity treatment.
- Early intervention is key to preventing severe liver damage.
- Accessibility of medications is a major concern.
- Comparative studies are essential for evaluating new treatments.
- Future treatments may include innovative delivery methods.
Chapters
00:00 Introduction to MASH and Semaglutide Study
04:29 Understanding Metabolic Dysfunction and Its Implications
08:02 Essence Trial: Semaglutide's Impact on MASH
12:58 Comparative Analysis of New Treatments for MASH
17:30 The Future of Obesity Treatment and Drug Accessibility
Join Vineyard - Dr. Spencer's online clinic
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
For the best experience, listen in Metacast app for iOS or Android